Enliven Therapeutics, Inc. ELVN R2K
Healthcare · Biotechnology · United States
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
READ MORE ›$39.57
+122.68% 1Y
Market & Price
Market Cap
$2.41B
Current Price
$39.57
High / Low (52W)
$48.11 / $15.14
Beta
0.45
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$7.45
Price to Book
5.31
P/S
-
EV/EBITDA
-16.94
Dividend Yield
-
Profitability & Returns
ROCE
-26.04%
ROE
-26.64%
ROA
-18.86%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.38
EPS (TTM)
$-1.64
Balance Sheet & Liquidity
Debt/Equity
0.07
Quick Ratio
39.38
Current Ratio
40.32
Debt
$302.00K
Total Assets
$476.17M
Current Assets
$474.88M
Working Capital
$458.31M
Ownership
Promoter Holding
7.52%
Chg in Prom Hold
-
FII / Inst Holding
104.96%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.96B
Total Revenue (TTM)
-
EBITDA
$-115.58M
Free Cash Flow
$-46.08M
Operating Cash Flow
$-65.47M
Shares Outstanding
60.90M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-58.44%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -58.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELVN Enliven Therapeutics, Inc. R2K | 39.57 | - | $2.41B | - | -26.04% | -26.64% | - | -58.44% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.69M | 28.58M | 25.10M | 34.28M | 27.82M |
| Operating Income | -4.19M | -5.56M | -6.88M | -7.35M | -10.30M | -12.49M | -10.28M | -13.17M | -13.66M | -8.68M | -9.02M | -10.93M | -16.42M | -20.13M | -24.25M | -25.99M | -24.60M | - | - | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -31.62M | -28.50M | -25.03M | -34.24M | -27.81M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | 0 | 0 | 0 | - |
| Net Income | -4.19M | -5.40M | -6.62M | -7.21M | -10.20M | -12.42M | -10.26M | -13.16M | -13.65M | -8.67M | -8.89M | -10.55M | -14.72M | -16.72M | -20.77M | -22.74M | -19.95M | - | - | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M |
| Diluted EPS | - | - | - | - | - | - | - | -0.74 | -0.74 | -3.01 | -2.86 | -3.27 | -0.80 | -0.41 | -0.51 | -0.54 | -0.41 | - | - | -0.57 | -0.49 | -0.32 | -0.48 | -0.38 |
| R&D Expense | 3.56M | 4.37M | 5.14M | 5.79M | 7.87M | 9.53M | 7.12M | 10.07M | 10.40M | 7.06M | 7.94M | 7.83M | 11.88M | 15.18M | 19.61M | 19.97M | 18.83M | 21.26M | - | 24.89M | 21.49M | 18.23M | - | 20.69M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 38.79M | 83.53M | 104.55M | 119.66M |
| Operating Income | -24.12M | -41.70M | - | -38.79M | -83.53M | -104.55M | -119.66M |
| EBITDA | - | - | - | -38.58M | -83.23M | -104.24M | -119.39M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -37.66M | -71.58M | -88.79M | -103.69M |
| Tax Provision | - | - | - | - | 0 | 232.00K | 0 |
| Net Income | -23.46M | -41.36M | - | -37.66M | -71.58M | -89.02M | -103.69M |
| Diluted EPS | - | - | -0.60 | -0.92 | -2.01 | -1.89 | - |
| R&D Expense | 19.01M | 32.15M | 38.44M | 31.02M | 64.57M | 80.78M | 85.86M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -58.44% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +122.68% |
| 6 Months: | +82.35% |
| 3 Months: | +33.28% |
| 1 Month: | -6.67% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 33.30M | 90.84M | - | 83.30M | 271.87M | 325.76M | 476.17M |
| Current Assets | - | - | - | - | 77.75M | 266.15M | 318.13M | 474.88M |
| Cash & Equivalents | - | 4.94M | 47.70M | - | 75.54M | 100.14M | 124.12M | 98.90M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.38M | 6.41M | - | 160.12M | 25.96M | 15.91M | 16.57M |
| Current Liabilities | - | 4.20M | 6.25M | - | 9.71M | 25.89M | 15.91M | 16.57M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 323.00K | 335.00K | 0 | 399.00K |
| Total Equity | -26.32M | -48.85M | 84.44M | - | -76.83M | 245.91M | 309.85M | 459.60M |
| Shares Outstanding | - | - | - | - | 41.10M | 41.29M | 48.94M | 59.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.88M | -37.40M | - | -32.08M | -61.27M | -73.19M | -70.30M |
| Investing Cash Flow | -24.06M | -16.72M | - | -612.00K | -148.41M | -36.00M | -173.84M |
| Financing Cash Flow | 43.58M | 96.88M | - | -1.80M | 234.29M | 133.16M | 218.87M |
| Capital Expenditure | - | - | - | -612.00K | -149.00K | -44.00K | -158.00K |
| Free Cash Flow | - | - | - | -32.69M | -61.42M | -73.24M | -70.46M |
| Net Change in Cash | - | - | - | -34.49M | 24.61M | 23.98M | -25.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 48.0% | -49.0% | - | 49.0% | -29.1% | -28.7% | -22.6% |
| ROCE % | -82.9% | -49.3% | - | -52.7% | -34.0% | -33.7% | -26.0% |
Shareholding Pattern
Insiders
7.52%
Institutions
104.96%
Public Float
113.49%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Orbimed Advisors LLC. | 13.07% | 7.96M | $314.96M |
| 2 | FMR, LLC | 11.21% | 6.83M | $270.23M |
| 3 | Polar Capital Holdings PLC | 8.32% | 5.07M | $200.46M |
| 4 | Blackrock Inc. | 6.05% | 3.68M | $145.80M |
| 5 | Commodore Capital Lp | 5.38% | 3.27M | $129.59M |
| 6 | Vestal Point Capital, LP | 5.34% | 3.25M | $128.60M |
| 7 | Bellevue Group AG | 3.81% | 2.32M | $91.84M |
| 8 | Vanguard Capital Management LLC | 3.56% | 2.17M | $85.79M |
| 9 | Fairmount Funds Management LLC | 3.05% | 1.86M | $73.43M |
| 10 | Citadel Advisors Llc | 2.86% | 1.74M | $69.01M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELVN
No recent headlines available.